MIRA Pharmaceuticals, Inc. (MIRA)
NASDAQ: MIRA · Real-Time Price · USD
1.060
+0.060 (6.00%)
At close: Dec 20, 2024, 4:00 PM
1.080
+0.020 (1.89%)
After-hours: Dec 20, 2024, 5:55 PM EST
MIRA Pharmaceuticals Stock Forecast
Stock Price Forecast
The 2 analysts with 12-month price forecasts for MIRA stock have an average target of 14, with a low estimate of 11 and a high estimate of 17. The average target predicts an increase of 1,220.75% from the current stock price of 1.06.
Analyst Consensus: Strong Buy
* Price targets were last updated on Sep 30, 2024.
Analyst Ratings
The average analyst rating for MIRA stock from 2 stock analysts is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
Rating | Oct '24 | Nov '24 | Dec '24 |
---|---|---|---|
Strong Buy | 2 | 2 | 2 |
Buy | 0 | 0 | 0 |
Hold | 0 | 0 | 0 |
Sell | 0 | 0 | 0 |
Strong Sell | 0 | 0 | 0 |
Total | 2 | 2 | 2 |
Latest Forecasts
Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
---|---|---|---|---|---|---|---|
Rodman & Renshaw | Rodman & Renshaw | Strong Buy Initiates $17 | Strong Buy | Initiates | $17 | +1,503.77% | Sep 30, 2024 |
Ascendiant Capital | Ascendiant Capital | Strong Buy Initiates $11 | Strong Buy | Initiates | $11 | +937.74% | Aug 5, 2024 |
Financial Forecast
Revenue This Year
n/a
Revenue Next Year
n/a
EPS This Year
-0.57
from -0.65
EPS Next Year
-0.50
from -0.57
Revenue Forecast
Revenue | 2024 | 2025 | 2026 |
---|---|---|---|
High | n/a | n/a | 579.6M |
Avg | n/a | n/a | 281.5M |
Low | n/a | n/a | n/a |
Revenue Growth
Revenue Growth | 2024 | 2025 | 2026 |
---|---|---|---|
High | - | - | - |
Avg | - | - | - |
Low | - | - | - |
EPS Forecast
EPS | 2024 | 2025 | 2026 |
---|---|---|---|
High | -0.55 | -0.46 | -0.57 |
Avg | -0.57 | -0.50 | -0.55 |
Low | -0.59 | -0.53 | -0.53 |
EPS Growth
EPS Growth | 2024 | 2025 | 2026 |
---|---|---|---|
High | - | - | - |
Avg | - | - | - |
Low | - | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.